Lung Cancer
Conditions
Keywords
Sweden
Brief summary
The goal of this clinical trial is to investigate if weekly symptom monitoring of patients with advanced lung cancer is associated with better survival and improved quality of life compared to standard follow-up. Each week, participants in the intervention group will be asked to respond to an electronic weekly questionnaire covering 11 items related to current health status.
Detailed description
This is a prospective, multicentre, randomized, two-armed, open-label trial in which participants will be randomised to standard follow-up according to current management guidelines for lung cancer (control arm) or with the addition of weekly web-based symptom monitoring (intervention arm). Both study groups will be asked to fill out quality of life questionnaires before randomisation and every three months. In addition to comparing survival and quality of life, the study will also assess progression free survival, performance status, eligibility for second line anti-neoplastic treatment and health care consumption. All subjects will be followed for 24 months. Updated data on survival will also be collected up to 5-years. By innovative use of an IT platform already in use in Swedish cancer care, this trial will evaluate potential benefits of systematic symptom monitoring in patients with advanced lung cancer. If corroborating earlier reports of marked survival benefits, the results of this trial could change clinical practice and current guidelines for follow-up of lung cancer patients.
Interventions
OTHERWeekly symptom monitoring
Patients randomized to the intervention arm will be invited to respond to a web-based weekly 11-item signs- and symptoms questionnaire
Sponsors
Uppsala University Hospital
Gävle Hospital
Mats Lambe
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically or cytology proven non-small cell lung cancer (NSCLC) * NSCLC stage III or IV * ≥ 18 years * ECOG performance status 0- 2 * Eligible patients should have initiated first-line treatment for advanced or metastatic disease with chemotherapy and/or immunotherapy, radiochemotherapy or targeted treatment * Patients are eligible for inclusion if they have responded to first-line treatment with stable disease, or better, at the first radiological evaluation performed up to six months after start of treatment * Stable disease, or better, on radiological assessment within 28 days of enrolment (CT scan or FDG-PET/CT. Cerebral MRI if known brain metastasis) * Initial web-based application score of ≤ 6 * Basic computer literacy * Bank-ID (electronic identification system) and access to 1177 Vårdguiden * The subject has given written consent to participate in the study
Exclusion criteria
* Symptomatic brain metastases * Pregnancy, breastfeeding, or planned pregnancy * Persons under guardianship or deprived of liberty * Mental inability, reluctance or language difficulties that result in difficulty understanding the meaning of study participation * Treatment or disease which, according to the investigator, can affect treatment or study results * Ongoing participation in another interventional clinical study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | From date of randomization until the date of death from any cause, assessed up to 60 months. | Overall survival |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Performance status | At baseline and at each clinical visit (approximately every 3-4 months), assessed up to 24 months. | Performance status will be evaluated according to the ECOG Perfomance Status Scale (Scale 0-5: 0 = fully active, able to carry on all pre-disease performance without restriction, 5=dead). |
| Proportion of patients starting second-line anti-neoplastic treatment | Assessed up to 24 months. | Proportion of patients starting second-line anti-neoplastic treatment within 12 weeks from date of confirmed disease progression after randomization. |
| Progression free survival | From date of randomization until the date of first confirmed disease progression as judged by the investigator, assessed up to 24 months. | First confirmed disease progression |
| Symptoms of depression | At baseline and every three months, assessed up to 24 months. | Assessed by the Patient Health Questionnaire (PHQ9). Score 0 (no symptoms) to 27 (severe symptoms). |
| Number of days of in-hospital care | Assessed up to 24 months. | Health care consumption will be assessed as number of days of in-hospital care during study participation. |
| Quality of life | At baseline and every three months, assessed up to 24 months. | Assessed by EORTC QLQ-C30-LC13 questionnaire. The QLQ-C30 is composed of both multi-item scales and single-item measures. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems. |
Contacts
Primary ContactMats P Lambe, MD, PhD
Backup ContactSandra Irenaeus, MD,PhD
Outcome results
None listed